Thank you. That's an excellent question.
It was not the intent of the reference panel to see that all available drugs would be covered through a national formulary. Those that were evidence based and judged to offer the best course of treatment at a reasonable price are those that would be listed, as they are in other countries with national formularies. Nevertheless, it was important to members of the reference panel to preserve an avenue through which patients could still exercise some choice in the medicines they access. They see the private insurance market as an opportunity for supplemental coverage to provide access to those additional drugs.